The EPS miss is modest and the narrowed guidance provides a floor, but the oral tobacco segment weakness (revenue -5.3%, OCI -8.0%) and ongoing cigarette volume declines (-3.2%) are structural headwinds. Monitor the on! PLUS national rollout and USSTC consolidation for margin recovery. The stock's high dividend yield (~7.5%) and buyback provide downside support, but volume trends warrant caution.
Price Chart
Executive Summary
Altria reported Q2 2026 adjusted diluted EPS of $1.48, a 2.8% YoY increase but a 1.3% miss vs. consensus of $1.50. Net revenues were essentially flat at $6.1B (+0.1% YoY), slightly above the $5.35B consensus. The company narrowed its full-year 2026 adjusted EPS guidance to $5.61-$5.72 (from $5.56-$5.72), raising the lower end. Smokeable segment adjusted OCI grew 2.4% on higher pricing, but oral tobacco segment adjusted OCI fell 8.0% on lower volume and higher promotions. The stock is likely to trade modestly lower on the EPS miss, partially offset by the narrowed guidance range.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted diluted EPS of $1.48 missed consensus of $1.50 by 1.3%
- Q2 2026 net revenues of $6.1B were essentially flat YoY (+0.1%)
- Narrowed FY2026 adjusted EPS guidance to $5.61-$5.72 (from $5.56-$5.72), raising the lower end
- Smokeable segment adjusted OCI +2.4% YoY; adjusted OCI margins +0.3pp to 64.8%
- Oral tobacco segment adjusted OCI -8.0% YoY; adjusted OCI margins -2.0pp to 66.7%
- Domestic cigarette shipment volume -3.2% (adjusted -4.5% for trade inventory)
- Oral tobacco shipment volume -8.5% (adjusted -2% for trade inventory)
- Repurchased 0.8M shares for $55M in Q2; $665M remaining under $2B buyback program
- Paid $1.8B in dividends in Q2; $3.6B in first half
- Expects 2026 capex of $375M-$450M, up from prior $300M-$375M, for USSTC facilities consolidation
Financial Impact
Q2 adjusted EPS miss of ~$0.02 vs consensus; narrowed FY guidance implies ~$0.05 higher midpoint vs prior range
Risk Factors
- Continued cigarette volume declines (-4% adjusted) and discount share shift pressuring margins
- Oral tobacco segment revenue -5.3% and OCI -8.0% on volume losses and promotional investment
- Litigation costs: $95M in Q2 tobacco/health litigation charges vs $4M in Q2 2025
- USSTC facilities consolidation costs ($88M in Q2) and higher capex guidance
- NJOY ACE remains off market for all of 2026, limiting smoke-free growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000764180-26-000093 |
| Document: mo-20260730.htm | 0000764180-26-000093 |
| Document: 0000764180-26-000093-index-headers.html | 0000764180-26-000093 |
| Document: 0000764180-26-000093-index.html | 0000764180-26-000093 |
| Document: 0000764180-26-000093.txt | 0000764180-26-000093 |
| 8-K Data (Synthetic) | 0000764180-26-000093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | 8-K | $68.65 $69.13 | ▲ +0.70% | ▲ +0.44% | $67.07 (−2.31%) |
Jul 30, 2026 9w ago | 8-K | $67.94 $67.67 | ▼ −0.40% | ▼ −4.36% | $67.07 (−1.29%) |
May 28, 2026 18w ago | Insider Cluster | $71.97 $73.21 | ▲ +1.73% | ▲ +4.42% | $67.07 (−6.81%) |
May 27, 2026 18w ago | 10-K/A | $72.13 $72.07 | ▼ −0.08% | ▲ +2.22% | $67.07 (−7.02%) |
Apr 2, 2026 26w ago | DEFA14A | $65.76 $72.65 | ▲ +10.48% | ▲ +0.60% | $67.07 (+1.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access